In-vivo Immune Analysis of Capsular Type Ia Antigen of Streptococcus Agalactiae Encapsulated with PLGA
Main Article Content
Abstract
Abstract
Background: Streptococcus agalactiae (S. agalactiae) due to the polysaccharide capsule and causing invasive infections, bacteremia, pneumonia, and meningitis in neonatal with 5% mortality considered the most critical pathogen. In order to increase the immunity level by the capsular type Ia antigen of S. agalactiae, conjugated polydlyl lactide-co-glycolide nanoparticles (PLGA_NP), we proposed a more effective vaccine against infections caused by S. agalactiae. In addition, the cytotoxicity of the NPs as a carrier in the fabrication of the nano-vaccine in the animal model of rats was investigated.
Materials & methods: Isolation of capsules from S. agalactiae, and preparation of PLGA nanoparticles containing type Ia capsules done. After conjugating the PLGA_NP with type Ia capsules, it was characterized using spectroscopy techniques. Rat vaccination and immunization process, rat survival model, spleen culture method on rats and neonatal rats, and opsonophagocytosis test were performed.
Results: The zeta potential of PLGA_NP was -19 mv, and for the conjugated capsule (CPS)-PLGA was -10.34 mv. The size of PLGA-CPS is 256.5 nm. The mean of the pathogenic strain of S. agalactiaeafter exposure to the immune system of the CPS-PLGA group was lower than in other experimental groups. Reduced growth of S. agalactiae colonies in the vaccine candidate group compared to the other groups reported (p < 0.05), and in rat opsonophagocytosis test, the CPS-PLGA vaccine candidate group has the lowest growth value in the percentage of grown colonies compared to other tested groups (p < 0.05).
Conclusion: It can be concluded that the potential performance of the CPS-PLGA vaccine candidate group is ineffective stimulation and enhancement of infection for diagnosis. On the other hand, according to data analysis, this vaccine group has a significant difference from other vaccine groups (p < 0.05). The prepared antigen can be used as a candidate vaccine to treat congenital infections and premature invasive neonatal infections in the animal model of rats due to its high efficacy in infection.
Downloads
Article Details
Copyright (c) 2024 Mirtalebi F, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Parivash Ghaderinia, Department of Microbiology, College of Science agriculture and modern technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
Mrs.Parivash Ghaderinia now working in role:
Department of Microbiology, Assistant Professor, Zanjan Branch, Islamic Azad University, Zanjan, Iran
Chaiwarith R, Jullaket W, Bunchoo M, Nuntachit N, Sirisanthana T, Supparatpinyo K. Streptococcus agalactiae in adults at Chiang Mai University Hospital: a retrospective study. BMC infectious diseases. 2011;11(1):1-7. Available from: https://doi.org/10.1186/1471-2334-11-149
Raabe VN, Shane AL. Group B streptococcus (Streptococcus agalactiae). Microbiology spectrum. 2019;7(2):7.2. 17. Available from: https://doi.org/10.1128/microbiolspec.gpp3-0007-2018
Cieslewicz MJ, Chaffin D, Glusman G, Kasper D, Madan A, Rodrigues S, et al. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infection and immunity. 2005;73(5):3096-103. Available from: https://doi.org/10.1128/iai.73.5.3096-3103.2005
Bianchi-Jassir F, Paul P, To K-N, Carreras-Abad C, Seale AC, Jauneikaite E, et al. Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine. 2020; 38(43):6682-6694. Available from: https://doi.org/10.1016/j.vaccine.2020.08.052
Pietrocola G, Arciola CR, Rindi S, Montanaro L, Speziale P. Streptococcus agalactiae Non-Pilus, Cell Wall-Anchored Proteins: Involvement in Colonization and Pathogenesis and Potential as Vaccine Candidates. Frontiers in Immunology. 2018;9(602). Available from: https://doi.org/10.3389/fimmu.2018.00602
Berends ET, Kuipers A, Ravesloot MM, Urbanus RT, Rooijakkers SH. Bacteria under stress by complement and coagulation. FEMS microbiology reviews. 2014;38(6):1146-71. Available from: https://doi.org/10.1111/1574-6976.12080
Yousefi Avarvand A, Khademi F, Ghazvini K, Nakhzari Moghadam M, Meshkat Z. Colonization rate of Streptococcus agalactiae in pregnant women in Iran: a systematic review. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2017;19(40):45-54. Available from: https://doi.org/10.22038/ijogi.2017.8446
Lim S, Rajagopal S, Jeong YR, Nzegwu D, Wright ML. Group B Streptococcus and the vaginal microbiome among pregnant women: a systematic review. PeerJ. 2021;9:e11437. Available from: https://doi.org/10.7717/peerj.11437
Han MY, Xie C, Huang QQ, Wu QH, Deng QY, Xie TA, et al. Evaluation of Xpert GBS assay and Xpert GBS LB assay for detection of Streptococcus agalactiae. Annals of Clinical Microbiology and Antimicrobials. 2021;20(1):1-11. Available from: https://doi.org/10.1186/s12941-021-00461-8
Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig M-J, Bartels DB, et al. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics. 2006;117(6):e1139-e45. Available from: https://doi.org/10.1542/peds.2005-2481
Betriu C, Culebras E, Gómez M, Rodríguez-Avial I, Sánchez B, Agreda M, et al. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrobial agents and chemotherapy. 2003;47(3):1112-4. Available from: https://doi.org/10.1128/aac.47.3.1112-1114.2003
De Francesco M, Caracciolo S, Gargiulo F, Manca N. Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy. European journal of clinical microbiology & infectious diseases. 2012;31(8):1741-7. Available from: https://doi.org/10.1007/s10096-011-1495-4
Peechakara BV, Basit H, Gupta M. Ampicillin. StatPearls [Internet]. 2020. Available from: https://www.statpearls.com/ub/Topic/ampicillin
Bolukaoto JY, Monyama CM, Chukwu MO, Lekala SM, Nchabeleng M, Maloba MR, et al. Antibiotic resistance of Streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa. BMC research notes. 2015;8(1):1-7. Available from: https://doi.org/10.1186/s13104-015-1328-0
Butler JC, Hofman J, Cetron MS, Elliott JA, Facklam RR, Breiman RF, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. Journal of Infectious Diseases. 1996;174(5):986-93. Available from: https://doi.org/10.1093/infdis/174.5.986
Gu P, Wusiman A, Zhang Y, Liu Z, Bo R, Hu Y, et al. Rational design of PLGA nanoparticle vaccine delivery systems to improve immune responses. Molecular pharmaceutics. 2019;16(12):5000-12. Available from: https://doi.org/10.1021/acs.molpharmaceut.9b00860
Zhang L, Zeng Z, Hu C, Bellis SL, Yang W, Su Y, et al. Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines. Biomaterials. 2016;77:307-19. Available from: https://doi.org/10.1016/j.biomaterials.2015.11.009
Poon C, Patel AA. Organic and inorganic nanoparticle vaccines for prevention of infectious diseases. Nano Express. 2020;1(1):012001. Available from: https://iopscience.iop.org/article/10.1088/2632-959X/ab8075
Wibowo D, Jorritsma SH, Gonzaga ZJ, Evert B, Chen S, Rehm BH. Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials. 2020:120597. Available from: https://doi.org/10.1016/j.biomaterials.2020.120597
Ma YP, Ke H, Liang ZL, Ma JY, Hao L, Liu ZX. Protective efficacy of cationic-PLGA microspheres loaded with DNA vaccine encoding the sip gene of Streptococcus agalactiae in tilapia. Fish & shellfish immunology. 2017;66:345-53. Available from: https://doi.org/10.1016/j.fsi.2017.05.003
Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. Journal of Biomaterials Science, Polymer Edition. 2006;17(3):247-89. Available from: https://doi.org/10.1163/156856206775997322
Choi MJ, Noh JY, Jang A-Y, Cheong HJ, Kim WJ, Song DJ, et al. Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus. Human vaccines & immunotherapeutics. 2020;16(6):1338-44. Available from: https://doi.org/10.1080/21645515.2019.1688036
Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. 2010. Available from: https://pubmed.ncbi.nlm.nih.gov/21088663/
Murray PR, Pfaller MA. Medical microbiology (8th ed.), Elsevier Health Sciences, UK (2015), pp. 192. Available from: https://www.google.co.in/books/edition/Medical_Microbiology/Gx3mCgAAQBAJ?hl=en
Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clinical infectious diseases. 2017;65(suppl_2):S100-S11. Available from: https://doi.org/10.1093/cid/cix658
Khademi F, Sahebkar A. Group B streptococcus drug resistance in pregnant women in Iran: a meta-analysis. Taiwanese Journal of Obstetrics and Gynecology. 2020;59(5):635-42. Available from: https://doi.org/10.1016/j.tjog.2020.07.002
Ke X, Chen X, Liu Z, Lu M, Gao F, Cao J. Immunogenicity of the LrrG protein encapsulated in PLGA microparticles in Nile tilapia (Oreochromis niloticus) vaccinated against Streptococcus agalactiae. Aquaculture. 2017;480:51-7. Available from: https://doi.org/10.1016/j.aquaculture.2017.08.003
Kaneko K, Miyaji EN, Gonçalves VM, Ferreira DM, Solórzano C, MacLoughlin R, et al. Evaluation of polymer choice on immunogenicity of chitosan-coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro. International Journal of Pharmaceutics. 2021;599:120407. Available from: https://doi.org/10.1016/j.ijpharm.2021.120407
Hasan MW, Haseeb M, Ehsan M, Gadahi JA, Naqvi MA-u-H, Wang QQ, et al. Nanoparticles (PLGA and Chitosan)-entrapped ADP-ribosylation factor 1 of Haemonchus contortus enhances the immune responses in ICR mice. Vaccines. 2020;8(4):726. Available from: https://doi.org/10.3390/vaccines8040726
Pumchan A, Krobthong S, Roytrakul S, Sawatdichaikul O, Kondo H, Hirono I, et al. Novel chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile tilapia (Oreochromis niloticus Linn.). Scientific reports. 2020;10(1):1-13. Available from: https://doi.org/10.1038/s41598-019-57283-0
Wang Q, Sun X, Huang X, Huang J, Hasan MW, Yan R, et al. Nanoparticles of Chitosan/Poly (D, L-Lactide-Co-Glycolide) Enhanced the Immune Responses of Haemonchus contortus HCA59 Antigen in Model Mice. International Journal of Nanomedicine. 2021;16:3125. Available from: https://doi.org/10.2147/IJN.S301851
Tamarov K, Näkki S, Xu W, Lehto V-P. Approaches to improve the biocompatibility and systemic circulation of inorganic porous nanoparticles. Journal of Materials Chemistry B. 2018;6(22):3632-49. Available from: https://doi.org/10.1039/c8tb00462e
Locatelli E, Franchini MC. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. Journal of Nanoparticle Research. 2012;14(12):1-17. Available from: https://ui.adsabs.harvard.edu/abs/2012JNR....14.1316L/abstract